A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

Vaccine

Volumn 34, Issue 25, 2016, Pages 2847-2854

  Falloon, Judith ^a   Ji, Fei ^a,e   Curtis, Craig ^b   Bart, Stephan ^c   Sheldon, Eric ^d   Krieger, Diane ^d,e   Dubovsky, Filip ^a   Lambert, Stacie ^a   Takas, Therese ^a   Villafana, Tonya ^a   Esser, Mark T ^a  

^a MEDIMMUNE   (United States)

^b Central Florida Pain Centers   (United States)

^c Optimal Research   (United States)

^d MIAMI RESEARCH ASSOCIATES   (United States)

^e NONE   (United States)

Author keywords

Adjuvant; Adult; Cell mediated immunity; Respiratory syncytial virus; Vaccine

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; HUMAN RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; EMULSION; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; GLUCOPYRANOSYL LIPID-A; GLUCOSIDE; IMMUNOGLOBULIN G; LIPID A; NEUTRALIZING ANTIBODY; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ABSCESS; ADULT; AGED; ARTICLE; BLADDER CANCER; CELLULAR IMMUNITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HUMORAL IMMUNITY; HYPOTHYROIDISM; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS INFECTION; UNSPECIFIED SIDE EFFECT; VIRAL GASTROENTERITIS; AGONISTS; BLOOD; CLINICAL TRIAL; EMULSION; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; EMULSIONS; FEMALE; GLUCOSIDES; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; LIPID A; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TOLL-LIKE RECEPTOR 4; VIRAL FUSION PROTEINS;

EID: 84964689439     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.04.002     Document Type: Article

References (32)

1. United States Centers for Disease Control and Prevention Respiratory syncytial virus infection (RSV). Trends and Surveillance 2015, [accessed 11.06.15]. http://www.cdc.gov/rsv/research/us-surveillance.html.
2. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759. 10.1056/NEJMoa043951.
3. Widmer K., Griffin M.R., Zhu Y., Williams J.V., Talbot H.K. Respiratory syncytial virus- and human metapneumovirus-associated emergency department and hospital burden in adults. Influenza Other Respir Viruses 2014, 8:347-352. 10.1111/irv.12234.
4. Walsh E.E., Peterson D.R., Falsey A.R. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?. J Infect Dis 2007, 195:1046-1051. 10.1086/511986.
5. Bloom-Feshbach K., Alonso W.J., Charu V., Tamerius J., Simonsen L., Miller M.A., et al. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One 2013, 8:e54445. 10.1371/journal.pone.0054445.
6. Falsey A.R., McElhaney J.E., Beran J., van Essen G.A., Duval X., Esen M., et al. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 2014, 209:1873-1881. 10.1093/infdis/jit839.
7. Hardelid P., Pebody R., Andrews N. Mortality caused by influenza and respiratory syncytial virus by age group in England and Wales 1999-2010. Influenza Other Respir Viruses 2013, 7:35-45. 10.1111/j. 1750-2659.2012.00345.x.
8. Lee N., Lui G.C., Wong K.T., Li T.C., Tse E.C., Chan J.Y., et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 2013, 57:1069-1077. 10.1093/cid/cit471.
9. Fleming D.M., Taylor R.J., Lustig R.L., Schuck-Paim C., Haguinet F., Webb D.J., et al. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis 2015, 15:443. 10.1186/s12879-015-1218-z.
10. Falsey A.R., Singh H.K., Walsh E.E. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 2006, 78:1493-1497. 10.1002/jmv.20724.
11. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163:693-698. 10.1093/infdis/163.4.693.
12. Gessner B.D. The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly. Vaccine 2000, 18:1485-1494. 10.1016/S0264-410X(99)00425-9.
13. Meijboom M.J., Pouwels K.B., Luytjes W., Postma M.J., Hak E. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine 2013, 31:6254-6260. 10.1016/j.vaccine.2013.10.023.
14. Malloy A.M., Falsey A.R., Ruckwardt T.J. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol 2013, 372:211-231. 10.1007/978-3-642-38919-1_11.
15. Schanzer D.L., Langley J.M., Tam T.W. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respir Viruses 2008, 2:1-8. 10.1111/j. 1750-2659.2008.00035.x.
16. Walsh E.E., Peterson D.R., Falsey A.R. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004, 189:233-238. 10.1086/380907.
17. Cherukuri A., Patton K., Gasser R.A., Zuo F., Woo J., Esser M.T., et al. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine Immunol 2013, 20:239-247. 10.1128/CVI. 00580-12.
18. McLellan J.S., Yang Y., Graham B.S., Kwong P.D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 2011, 85:7788-7796. 10.1128/JVI. 00555-11.
19. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. 10.1542/peds.102.3.531.
20. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333. 10.1371/journal.pone.0016333.
21. Lambert S.L., Yang C.F., Liu Z., Sweetwood R., Zhao J., Cheng L., et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl lipid A. PLoS One 2012, 7:e51618. 10.1371/journal.pone.0051618.
22. Lambert S.L., Aslam S., Stillman E., MacPhail M., Nelson C., Ro B., et al. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One 2015, 10:e0119509. 10.1371/journal.pone.0119509.
23. McLellan J.S., Chen M., Leung S., Graepel K.W., Du X., Yang Y., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340:1113-1117. [Epub 2013 April 25]. 10.1126/science.1234914.
24. United States Centers for Disease Control and Prevention Vaccine administration: recommendations and guidelines 2015, [accessed 19.10.15]. http://www.cdc.gov/vaccines/recs/vac-admin/default.htm.
25. United States Food and Drug Administration Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials 2014, [accessed 19.10.15]. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm.
26. Patton K., Aslam S., Shambaugh C., Lin R., Heeke D., Frantz C., et al. Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques. Vaccine 2015, 33:4472-4478. 10.1016/j.vaccine.2015.07.025.
27. Maifeld S.V., Ro B., Mok H., Chu M., Yu L., Leonardson T., et al. Development and qualification of a dual-purpose, multiplex serology assay for the diagnosis of recent respiratory syncytial virus infection and assessment of vaccine immunogenicity. FOCiS 2015, Poster #F.59.
28. Patton K., Aslam S., Lin J., Yu L., Lambert S., Dawes G., et al. Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells. Clin Vaccine Immunol 2014, 21:628-635. 10.1128/CVI. 00736-13.
29. Shambaugh C., Azshirvani S., Yu L., Pache J., Maifeld S., Mok S., et al. Qualification of a fluorescence-based RSV microneutralization assay and the effect of complement enhancement on neutralization titers from subjects in a Phase 1a study that were vaccinated with RSV sF or RSV sF plus glucopyranasol lipid A-stable emulsion (GLA-SE) (MEDI7510) vaccine. Vaccines for the world 2015.
30. Geevarghese B., Weinberg A. Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age. Hum Vaccin Immunother 2014, 10:1047-1056. 10.4161/hv.27908.
31. Rossey I., Sedeyn K., De Baets S., Schepens B., Saelens X. CD8+ T cell immunity against human respiratory syncytial virus. Vaccine 2014, 32:6130-6137. 10.1016/j.vaccine.2014.08.063.
32. United States Centers for Disease Control and Prevention General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011, 60:1-64.